The use of oligonucleotides (i.e., “oligos”) was first proposed in the late 1970s, but has not achieved widespread popularity until recently. Developments in delivery method and target specificity for oligos have led to oligos’ resurgence in popularity. These therapies are particularly of interest because their mechanism of action allows for targeting virtually any nucleic acid…
WuXi AppTec Expands Site in California for Pharmaceutical R&D Services
WuXi STA And Regulus To Team Up On MicroRNA Development And Manufacturing
STA Pharmaceutical Co., Ltd., a WuXi AppTec group company and an open-access capability and technology platform for small molecule pharmaceutical development and manufacturing, and Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing. Under…